Symposium - European Medical Journal

Continue

Symposiums

EMJ Hematology 9 [Supplement 1] 2021 ft image
Hematology
10 Mins
13 Apr 2021

Time for TIM-3: Beyond Immune Checkpoint Inhibition

TIM-3 was first discovered in Prof Kuchroo’s laboratory in 2002. This lecture reviewed the history of the discovery of TIM-3, including…
EMJ Dermatology 9 [Supplement 4] 2021 feature image
Dermatology
10 Mins
29 Mar 2021

Advancing Breakthrough Innovative Treatment in Paediatric Dermatitis and Various Skin Disorders

Eczematous dermatitis (or eczema) includes AD, CD, and DD. This inflammatory skin reaction presents as erythema, vesicles, desquamation…
EMJ Cardiology 9 [Supplement 2] 2021 feature image
Cardiology
12 Mins
25 Mar 2021

Novel Insights into Cardiac Biomarkers in Atrial Fibrillation, Heart Failure, and Coronary Heart Disease | Advancing Understanding and Clinical Application of Cardiac Biomarkers

Oral anticoagulation is currently underused in AF management, with one-third of cases remaining silent and asymptomatic. The STROKESTOP…
EMJ 6.1 Feature Image
Oncology
11 Mins
23 Mar 2021

Addressing the Unmet Need in Treatment of Nonmelanoma Skin Cancers: Interviews with Two Key Opinion Leaders

Nonmelanoma skin cancers (NMSC) are a diverse group of cutaneous malignancies and are the most common forms of human neoplasia worldwide…
EMJ 6.1 Feature Image
Dermatology
15 Mins
23 Mar 2021

The Treatment Landscape of Atopic Dermatitis: Interviews with Three Consultant Dermatologists

Atopic dermatitis (AD), sometimes referred to as ‘atopic eczema’, is a common, chronic, pruritic, Type II inflammatory skin disease which is associated…
Hematology
8 Mins
23 Mar 2021

Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and the most frequent non-Hodgkin lymphoma (NHL) in adults, accounting for 30–40%…
EMJ Dermatology 9 [Supplement 3] 2021 Feature Image
Dermatology
11 Mins
25 Feb 2021

Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab

The indicative scaly, erythematous plaques of plaque psoriasis arise because of abnormal interactions between immune system cells and epidermal…
Rheumatology
10 Mins
19 Feb 2021

Diagnosis, Treatment Management, and the Genetic Basis of Psoriasis, Psoriatic Arthritis, and Spondyloarthritis

Psoriatic arthritis (PsA) is an inflammatory condition of the joints and the areas where tendons and ligaments connect with bone…